Form 4 for KRMD KORU Medical Systems, Inc.
Accepted 2024-03-15 00:00:00 ET · period of report 2024-03-13 · accession 0001161697-24-000150 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-15 | 2024-03-13 | KRMD | Tharby Linda M | Pres, CEO, Dir | A - Grant | $2.09 | +19.7K | 1.08M | +2% | +$41.1K | |
| 2024-03-15 | 2024-03-13 | KRMD | Tharby Linda M | Pres, CEO, Dir | F - Tax | $2.09 | -7,094 | 1.07M | -0.7% | -$14.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-13 | A | A | 19,681 | $2.09 | 1,076,537 | D | — | — | (F1) Shares earned per her employment agreement for bonus of which 70% was paid in cash and 30% paid in shares of the Company's common stock. (F2) Includes 200,000 in restricted stock awards that vest in 25% increments annually on 4/12/22,4/12/23, 4/12/24 and 4/12/25; 200,000 in restricted stock awards that vest based on a schedule of the Company's market capitalization prior to 3/15/27; 600,000 in restricted stock awards that vest based on a schedule of the Company's net sales growth targets for each of the fiscal years ended 12/31/22 through 12/31/25. |
| 2 | Common | Common Stock | 2024-03-13 | F | D | 7,094 | $2.09 | 1,069,443 | D | — | — | (F3) Represents shares of common stock withheld by the issuer in satisfaction of tax withholding obligations upon the issuance of common stock for the portion of the 2023 bonus paid out in equity (F2) Includes 200,000 in restricted stock awards that vest in 25% increments annually on 4/12/22,4/12/23, 4/12/24 and 4/12/25; 200,000 in restricted stock awards that vest based on a schedule of the Company's market capitalization prior to 3/15/27; 600,000 in restricted stock awards that vest based on a schedule of the Company's net sales growth targets for each of the fiscal years ended 12/31/22 through 12/31/25. |